Results 151 to 160 of about 8,927 (183)

Long-term safety and efficacy in paediatric psoriasis: Remaining challenges. [PDF]

J Eur Acad Dermatol Venereol
Droitcourt C, Goaziou NL.
europepmc   +1 more source

Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years. [PDF]

Rheumatology (Oxford)
Mease PJ, Coates LC, Gaillez C, Shew A, Bao W, Ritchlin CT.   +5 more
europepmc   +1 more source

Study protocol for testing pharmacological conditioning as a drug dose reduction strategy in patients with psoriasis in a randomised controlled trial. [PDF]

BMJ Open
Savvidou P, Hölsken S, Krefting F, Benson S, Sondermann W.   +4 more
europepmc   +1 more source

Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study. [PDF]

Rheumatology (Oxford)
Zhao MH, Cons Molina F, Aroca G, Tektonidou MG, Mathur A, Tangadpalli R, Sun R, Martin R, Pellet P, Ngoc Phuong Huynh T.   +9 more
europepmc   +1 more source

Reconsidering Efficacy and Safety: A Critical Appraisal of Repurposing Anti-inflammatory Targeted Drugs in Darier disease. [PDF]

Acta Derm Venereol
Burle E, Mazereeuw-Hautier J, Severino-Freire M.   +2 more
europepmc   +1 more source

Infliximab-induced paradoxical psoriasis successfully treated with secukinumab: A case report. [PDF]

SAGE Open Med Case Rep
Te B, Roesler J, Kunimoto B.
europepmc   +1 more source

Successful Treatment of Two Rare Pediatric Keratinization Disorders with Secukinumab: Epidermolytic Ichthyosis and PRP-GPP Overlap. [PDF]

Psoriasis (Auckl)
Xu Q, Zhang J.
europepmc   +1 more source

Baseline Clinical and Metabolic Predictors of 52-Week Durability of Secukinumab Response in Moderate-to-Severe Plaque Psoriasis. [PDF]

Clin Cosmet Investig Dermatol
Wang J, Li P.
europepmc   +1 more source

Retraction: Exploring the therapeutic potential of IL-17A inhibition in myasthenia gravis: a retrospective study on secukinumab. [PDF]

BMJ Neurol Open
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Secukinumab

Reactions Weekly
  +13 more sources